Jatin Shah

Jatin Shah is a declared insider of Karyopharm Therapeutics Inc. (senior executive), with filings sourced from SEC (Form 4). In total, 13 filings cover trades dated from 15 February 2020 to 17 February 2022.

On the open market, the record shows 1 purchase worth €166k and 6 sales worth €97k. Netting one side against the other leaves €69k of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants and 4 option exercises. So far in 2022, the count stands at no purchases and 2 sales.

Most recently, on 22 February 2022, the filings show an open-market sale worth €14k in Karyopharm Therapeutics Inc. The most recent open-market purchase was published on 11 May 2021, 1,992 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.